Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis

Claire Palles, Luke Freeman-Mills, Edward Arbe-Barnes, Nathalie Feeley, Laura Chegwidden, Helen Curley, Sara Galavotti, Connor Woolley, Jeremy Cheadle, Dmitri Mouradov, Oliver Sieber, Silvia Salatino, Steve Thorn, Anshita Goel, Juan Fernandez-Tajes, Sulochana Omwenga, Sujata Biswas, Timothy Maughan, · 2025

Read Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis by Claire Palles, Luke Freeman-Mills, Edward Arbe-Barnes, Nathalie Feeley, Laura Chegwidden, Helen Curley, Sara Galavotti, Connor Woolley, Jeremy Cheadle, Dmitri Mouradov, Oliver Sieber, Silvia Salatino, Steve Thorn, Anshita Goel, Juan Fernandez-Tajes, Sulochana Omwenga, Sujata Biswas, Timothy Maughan, (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13311953.txt.

Description

Claire Palles and colleagues investigate, in a 2025 study, how inherited and acquired mutations in the gene RNF43 contribute to colorectal cancer. Inherited loss-of-function variants were thought to cause a syndrome of many serrated polyps and early cancer. That picture came from selected families. The team examined nearly 49,823 cancer or polyp cases against 165,250 controls from large British cohorts. They compared them with tumor-acquired mutations in 2,722 cancers.

One multigenerational family did show the classic early-onset pattern. Most carriers, though, lacked multiple polyps or a striking family history. Some cancers clearly arose independently of the inherited variant. Inherited variants raised risk moderately, with an odds ratio of 2.696. The catch was position: risk rose only when the change sat in the gene's first half. Tumor-acquired changes in the second half still proved harmful, aided by partner mutations. Testing and counseling, the authors argue, should reflect this uneven risk.

Catalog record

CREATORClaire Palles, Luke Freeman-Mills, Edward Arbe-Barnes, Nathalie Feeley, Laura Chegwidden, Helen Curley, Sara Galavotti, Connor Woolley, Jeremy Cheadle, Dmitri Mouradov, Oliver Sieber, Silvia Salatino, Steve Thorn, Anshita Goel, Juan Fernandez-Tajes, Sulochana Omwenga, Sujata Biswas, Timothy Maughan,
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE77 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13311953

Browse the full library · About the Tower of Babel